Deficiency of Niemann-Pick C1 Like 1 Prevents Atherosclerosis in ApoE−/−Mice
- 1 April 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 27 (4) , 841-849
- https://doi.org/10.1161/01.atv.0000257627.40486.46
Abstract
Objective—The objective of this study was to determine whether the deficiency of Niemann-Pick C1 Like 1 (Npc1l1) prevents atherosclerosis in apoE null mice.Methods and Results—Npc1l1−/−/apoE null−/−mice were generated and found to have a significant reduction in cholesterol absorption (−77%) compared with wild-type or apoE−/−mice. Npc1l1/apoE−/−mice were fed a chow or Western diet for 24 weeks, then lipoprotein, hepatic, and biliary cholesterol, and atherosclerosis development was compared with apoE−/−, Npc1l1−/−, wild-type, and ezetimibe-treated apoE−/−mice. Chylomicron remnant/ VLDL cholesterol levels were reduced 80% to 90% in both chow and Western diet-fed Npc1l1/apoE−/−mice relative to apoE−/−mice. Male Npc1l1−/−and Npc1l1/apoE−/−mice were completely resistant to diet induced hypercholesterolemia, and both male and female mice were completely resistant to increases in hepatic and biliary cholesterol levels. Atherosclerosis was reduced 99% in aortic lesion surface area, 94% to 97% in innominate artery intimal lesion area, and >90% in aortic root lesion area in both male and female Npc1l1/apoE−/−mice relative to apoE−/−mice.Conclusions—Lack of Npc1l1, the molecular target of the cholesterol absorption inhibitor ezetimibe, in apoE−/−mice results in a significant reduction in cholesterol absorption and plasma cholesterol levels, and causes a nearly complete protection from the development of atherosclerosis, under both cholesterol-fed and non-cholesterol-fed conditions.Keywords
This publication has 14 references indexed in Scilit:
- NPC1L1: Evolution From Pharmacological Target to Physiological Sterol TransporterArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- mRNA and 18S–RNA coapplication–reverse transcription for quantitative gene expression analysisAnalytical Biochemistry, 2005
- Niemann-Pick C1 Like 1 (NPC1L1) Is the Intestinal Phytosterol and Cholesterol Transporter and a Key Modulator of Whole-body Cholesterol HomeostasisJournal of Biological Chemistry, 2004
- Atherosclerosis in the Apolipoprotein E–Deficient MouseArteriosclerosis, Thrombosis, and Vascular Biology, 2004
- Ezetimibe potently inhibits cholesterol absorption but does not affect acute hepatic or intestinal cholesterol synthesis in ratsBritish Journal of Pharmacology, 2003
- Deficiency of acyl CoA:cholesterol acyltransferase 2 prevents atherosclerosis in apolipoprotein E-deficient miceProceedings of the National Academy of Sciences, 2003
- The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogsMetabolism, 2001
- Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663British Journal of Pharmacology, 2000
- Discovery of 1-(4-Fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)- hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol AbsorptionJournal of Medicinal Chemistry, 1998
- Apolipoprotein E competitively inhibits receptor-dependent low density lipoprotein uptake by the liver but has no effect on cholesterol absorption or synthesis in the mouse.Proceedings of the National Academy of Sciences, 1995